NCIC Clinical Trials Group

Lung

Disease Site Committee Meeting Agenda

Fairmont Queen Elizabeth Hotel, Montreal, QC

Room: Jolliet
Sunday, May 2, 2010 – 8:00 AM – 1:00 PM

Chairs: G. Goss / Y. Ung

8:00 am  Welcome and Announcements  G. Goss
  • Update on site visit and review of research priorities for next 5 yrs

8:15 am  Subcommittee Reports:
  • Small Cell  P. Ellis
  • Radiation  Y. Ung
  • Mesothelioma and Thymoma  C. Lee
  • Correlative Sciences  M. Tsao

9:00 am  Non-Small Cell Lung Cancer:

  Surgical Adjuvant and Neoadjuvant and Locally Advanced Trials
  • BR.19 - Randomized trial of adjuvant gefitinib versus placebo after complete resection of Stage IB, II IIIA NSCLC  G. Goss
  • BR.2 - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-IIIA NSCLC  C. Butts
  • BR.5 - CALGB 140503 A Phase III randomized trial of lobectomy versus sub-lobar resection for small (<2cm) peripheral NSCLC  TBA
  • BR.16 - Randomized placebo controlled trial of adjuvant selenium in completely resected stage I NSCLC (ECOG)  TBA

9:45 am  BREAK

10:05 am  Advanced NSCLC:
  • BR.24 - (Update on Randomized trial of paclitaxel and carboplatin +/- AZD 2171) in advanced Non-SCLC and BRC.4-N0723 – A phase III biomarker validation study of second-line therapy in patients with advanced NSCLC randomized to pemetrexed versus erlotinib  G. Goss
  • BR.29 - A double blind randomized trial of cediranib versus placebo in patients receiving paclitaxel/carboplatin chemotherapy for the treatment of advanced or metastatic Non-Small Cell Lung cancer.  S. Laurie
  • BR26 - A double blind placebo controlled trial of PF-804 in advanced NSCLC  P. Ellis

continued on next page …
10:35 am  **Radiotherapy Study Update:**
  * BR.25 - Hypofractionated radiotherapy for medically inoperable NSCLC
  * BRC.1 - PCI in NSCLC
  * BR.27 - LUNG-ART Post-operative adjuvant radiation for completely resected N2 NSCLC

10:55 am  **Small Cell Lung Cancer:**
  * BR.28 - CONVERT – Once daily versus twice daily radiation for limited SCLC

11:05 am  **IND Studies:**
  * IND.183 - Phase II trial of sutent in 2nd-line treatment of malignant mesothelioma
  * IND.190 - Phase I-II trial of etoposide/cisplatin + IGFR1 inhibitor in extensive stage SCLC
  * IND 196 - Phase I/II c-met inhibitor/erlotinib
  * Report from the IND Committee

11:45 am  **PRO, Economic and Secondary Analyses of Lung Trials**
  * Quality of Life
  * Economic analyses active and planned
  * Database analyses

12:15 pm  **New Studies and Close**